The predictive value of serum Ang-5 and SHLP1 levels for the risk and prognosis of complications in acute cerebral infarction patients
Serum Ang-5 and SHLP1 levels in ACI
Abstract
Objective To investigate the levels of Survival of Motor Neurons Homolog Protein 1 (SHLP1) and serum Angiopoietin 5 (Ang-5) in patients with acute cerebral infarction (ACI) who also have brain-heart syndrome (BHS).
Methods The concurrent group consisted of 208 patients with BHS-complicated ACI who were hospitalized between January 2023 and June 2025, whereas the nonconcurrent group consisted of 220 patients with simple ACI who visited the hospital during the same time frame. The serum levels of SHLP1 and Ang-5 in the patients were assessed using an enzyme-linked immunosorbent assay. Pearson correlation analysis was used to investigate the relationships between the serum levels of Ang-5 and SHLP1 in patients with ACI complicated by BHS and the following indicators: left ventricular ejection fraction (LVEF), cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase isoenzyme (CK-MB), and others. The diagnostic value of serum Ang-5 and SHLP1 for BHS in patients with acute coronary insufficiency was evaluated using receiver operating characteristic (ROC) curves.
Results Serum SHLP1 level and LVEF were lower in the concurrent group than in the nonconcurrent group, although serum CK-MB, NT-proBNP, cTnI, and Ang-5 levels were greater in the concurrent group. Statistically, the differences were substantial (P<0.05). The serum SHLP1 level of patients with ACI and BHS was found to be positively connected with LVEF (P<0.05) and negatively correlated with CK-MB, NT-proBNP, and cTnI levels, according to the Pearson correlation analysis. LVEF was adversely linked (P<0.05) with the serum Ang-5 level, whereas CK-MB, NT-proBNP, and cTnI levels were positively correlated. Ang-5, CK-MB, NT-proBNP, and cTnI were risk factors for BHS in ACI patients (P<0.05), whereas higher serum SHLP1 levels and higher LVEF were protective factors for BHS in ACI patients (P<0.05), according to the results of multivariate logistic regression analysis. Based on the results of the ROC curve analysis, the area under the curve (AUC) for the combined diagnosis of blood Ang-5 and SHLP1 for ACI patients with BHS was 0.927, greater than the AUC for serum Ang-5 and SHLP1 alone (Z = 3.340, P = 0.001; Z = 3.541, P < 0.001).
Conclusion Patients with ACI complicated by BHS had low serum SHLP1 levels but high serum Ang-5 levels. The diagnostic value for ACI complicated by BHS can be increased by the combined detection of these two signs.
References
2.Yang F, Zhang P. Prevalence and Predictive factors of Post-Stroke Depression in Patients with Acute Cerebral Infarction. Alpha Psychiatry. 2024 Sep 1;25(5):592-597. doi: 10.5152/alphapsychiatry.2024.231381. PMID: 39553498; PMCID: PMC11562640.
3.Qiu T, Feng H, Shi Q, Fu S, Deng X, Chen M, Li H, Zhang Z, Xu X, Xiao H, Wang Z, Yu X, Tang J, Dai X. Dual-energy Computed Tomography (DECT) predicts the efficacy of contrast medium extravasation and secondary cerebral hemorrhage after stent thrombectomy in acute ischemic cerebral infarction. Biotechnol Genet Eng Rev. 2024 Apr;40(1):202-216. doi: 10.1080/02648725.2023.2183311. Epub 2023 Mar 9. PMID: 39312182.
4.Du W, Fan L, Du J. Neuroinflammation-associated miR-106a-5p serves as a biomarker for the diagnosis and prognosis of acute cerebral infarction. BMC Neurol. 2023 Jun 27;23(1):248. doi: 10.1186/s12883-023-03241-3. PMID: 37369997; PMCID: PMC10294433.
5.Ruan J, Zhou J, Li G, Peng T, Zhang J, Wei B. Circulating miR-505-5p as a Diagnostic Marker for Acute Cerebral Infarction and Its Predictive Value for Clinical Outcomes After Endovascular Mechanical Thrombectomy. Tohoku J Exp Med. 2025 May 24;266(1):59-67. doi: 10.1620/tjem.2024.J085. Epub 2024 Sep 5. PMID: 39231727.
6.Mo J, Liu L, Li Z, Hu Z, Tan Y, Long G. Diagnostic value of C-reactive protein/albumin ratio and TMTC1 in intracranial atherosclerotic stenosis in patients with acute cerebral infarction. Sci Rep. 2025 Mar 13;15(1):8653. doi: 10.1038/s41598-025-92714-1. PMID: 40082626; PMCID: PMC11906579.
7.Zhu X, Sun X, Chai Q, Min L, Li H, Sun Y, Bu C. Dysregulation of Serum UCA1 and Its Clinical Significance in Patients with Acute Cerebral Infarction. Ann Clin Lab Sci. 2023 Sep;53(5):719-725. PMID: 37945010.
8.Rao Z, Tan W, Wang J, Zhou Y, Yang X, Hu S. Predictive value of Cmmi-MHR combined with thromboelastography parameters in acute cerebral infarction. BMC Med Imaging. 2024 May 18;24(1):115. doi: 10.1186/s12880-024-01299-0. PMID: 38762466; PMCID: PMC11102274.
9.Lin S, Chen J. Clinical value of serum miR-943 as a diagnostic and prognostic biomarker for acute cerebral infarction and its mechanism of action by targeting BDNF. Arch Biochem Biophys. 2025 Oct 28;775:110667. doi: 10.1016/j.abb.2025.110667. Epub ahead of print. PMID: 41167448.
10.Wang T, Wang F, Dong X, Liu X, Cui Z, Shi Y. Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients. J Med Biochem. 2025 Aug 21;44(5):1092-1099. doi: 10.5937/jomb0-55111. PMID: 40951899; PMCID: PMC12433302.
11.Shen X, Gong C, Liu M, Jiang Y, Xu Y, Ge Z, Tao Z, Dong N, Liao J, Yu L, Fang Q. Effect of sacubitril/valsartan on brain natriuretic peptide level and prognosis of acute cerebral infarction. PLoS One. 2023 Sep 21;18(9):e0291754. doi: 10.1371/journal.pone.0291754. PMID: 37733793; PMCID: PMC10513241.
12.Liu L, Luo GQ, Liu Q, Yang ZY. Hemorrhagic risk factors after rt PA thrombolysis in acute cerebral infarction. Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5542-5551. doi: 10.26355/eurrev_202306_32791. PMID: 37401290.
13.Xia Y, Wei K, Jiang L, Zou D, Yang Y, Wu S, Hu F, Ma Y. Expression levels and clinical significance of serum miR-19a/CCL20 in patients with acute cerebral infarction. Open Med (Wars). 2024 Jul 2;19(1):20240977. doi: 10.1515/med-2024-0977. PMID: 38961881; PMCID: PMC11221218.
14.Huang J, Liao F, Tang J, Shu X. Development of a model for predicting acute cerebral infarction induced by nonvariceal upper gastrointestinal bleeding. Clin Neurol Neurosurg. 2023 Dec;235:107992. doi: 10.1016/j.clineuro.2023.107992. Epub 2023 Sep 29. PMID: 37944305.
15.Lin X, Wang W, Tao T, Zhang D, Mao L, He X. Synthetic role of miR-411-5p and CT perfusion information in predicting clinical outcomes after thrombolysis in acute cerebral infarction. Acta Neurol Belg. 2023 Apr;123(2):457-464. doi: 10.1007/s13760-022-02041-9. Epub 2022 Aug 6. PMID: 35933505.
16.Tang Y, Zhang J, Liu W, Jin W, Li S, Qian Z, Kong X, Zhang R, Hu J, Li B, Yuan W, Zhang Y. Analysis of carotid vulnerable plaque MRI high-risk features and clinical risk factors associated with concomitant acute cerebral infarction. BMC Cardiovasc Disord. 2023 Mar 30;23(1):173. doi: 10.1186/s12872-023-03199-7. PMID: 36997869; PMCID: PMC10064680.
17.Wang J, Yuan Y, Zhang Y, Wang M, Yan Y. Assessment of frailty status in patients with acute cerebral infarction and their relationship with serum markers. Am J Transl Res. 2024 Oct 15;16(10):6018-6028. doi: 10.62347/CWFR7413. PMID: 39544753; PMCID: PMC11558393.
18.Du J, Guo G, Du W. CT perfusion imaging parameters and serum miR-106a-5p predict short- and long-term prognosis in acute cerebral infarction patients after intravenous thrombolysis. Medicine (Baltimore). 2023 Aug 4;102(31):e34541. doi: 10.1097/MD.0000000000034541. PMID: 37543763; PMCID: PMC10402976.
19.Jian H, Wang F, Wang Y, Dou L. Clinical Significance of MicroRNA-330-3p in Plasma Level for Acute Cerebral Infarction. Cerebrovasc Dis. 2024;53(4):411-419. doi: 10.1159/000533605. Epub 2023 Sep 29. PMID: 37778331.
20.Liu ZZ, Lin WJ, Feng Y, Huang CL, Yan YF, Guo WY, Zhang H, Lei Z, Lu QL, Liu P, Lin XM, Wu SD. Plasma lncRNA LIPCAR Expression Levels Associated with Neurological Impairment and Stroke Subtypes in Patients with Acute Cerebral Infarction: A Prospective Observational Study with a Control Group. Neurol Ther. 2023 Aug;12(4):1385-1398. doi: 10.1007/s40120-023-00482-9. Epub 2023 May 17. PMID: 37195410; PMCID: PMC10310665.
21.Pei Q, Zhu R, Yang Y. Diagnostic Value of Contrast-Enhanced Ultrasound Combined with MiR-125b-5p in Acute Cerebral Infarction and Its Correlation with Carotid Plaque Neovascularization. Tohoku J Exp Med. 2025 Feb 6. doi: 10.1620/tjem.2025.J011. Epub ahead of print. PMID: 39909428.
22.Chen C, Ma F, Wen X, Liu X, Tang Q, Wu Y. Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. Curr Pharm Des. 2023;29(25):2009-2017. doi: 10.2174/1381612829666230622110753. PMID: 37349997.
23.Wang Y, Li L, Hu X, Huang L, Li Z. The value of thromboelastography in evaluating the efficacy of Xueshuantong combined with edaravone in the treatment of acute cerebral infarction. Medicine (Baltimore). 2024 Apr 26;103(17):e37954. doi: 10.1097/MD.0000000000037954. PMID: 38669396; PMCID: PMC11049688.
24.Tao Z, Zhou F, Zhang H, Qian M. Value of MRI T2 FLAIR Vascular Hyperintensities Combined with DWI ASPECTS in Predicting the Prognosis of Acute Cerebral Infarction with Endovascular Treatment. Curr Med Imaging. 2023;19(11):1273-1278. doi: 10.2174/1573405619666230201103813. PMID: 36725829; PMCID: PMC10339677.
Copyright (c) 2026 Qian Zhang, Xuehan Zhang, Shuli Wang, Wenqiong Xu, Lirong Wu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.